[ Back to EurekAlert! ] Public release date: 9-Jun-2009
[ | E-mail Share Share ]

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University in St. Louis

Researchers find how a common genetic mutation makes cancer radiation resistant

June 9, 2009 -- Many cancerous tumors possess a genetic mutation that disables a tumor suppressor called PTEN. Now researchers at Washington University School of Medicine in St. Louis have shown why inactivation of PTEN allows tumors to resist radiation therapy.

The PTEN gene produces a protein found in almost all tissues in the body. This protein acts as a tumor suppressor by preventing cells from growing and dividing too rapidly. Mutations in PTEN are frequently found in prostate cancer and endometrial cancer, melanoma and certain aggressive brain tumors.

Tumors with PTEN mutations are often resistant to radiation therapy, and Tej K. Pandita, Ph.D., a researcher with the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, and his colleagues have been trying to find out why. That information could enable researchers to develop drugs that overcome that resistance and increase the effectiveness of radiation treatments.

In an article to be published July 15, 2009, in the journal Cell Cycle and now available online, they demonstrate that PTEN-deficient cells have defective checkpoints. As cells grow and divide, they pass through several phases. Checkpoints operate during each phase and assess whether a cell is healthy enough to continue growing and dividing. If not - for example, if there is damage to genetic material resulting from radiation treatments signals from checkpoints should tell the cell to wait until repairs are made or should induce the cell to die.

The finding that checkpoints are affected in PTEN-deficient cells is contrary to some previous research, which had suggested instead that cells with PTEN mutations had defective DNA repair mechanisms. But Pandita showed that DNA repair is independent of PTEN function in tumor cells grown in the laboratory. That indicated that defective DNA repair is not the cause of the unstable genomes frequently seen in PTEN-deficient tumor cells and not the explanation for radiation resistance in these tumors.

"The defective checkpoints contribute to radioresistance," says Pandita, associate professor of radiation oncology and of genetics. "When a cell gets damaged by radiation, normally checkpoints will make it stop growing to repair the damage. If the checkpoints are working but the cell has a defective DNA repair system, the cell will be radiosensitive. But if the checkpoints don't operate, the cell can bypass DNA repair and continue to grow and divide. Then the cells are radioresistant."

The results indicate that to increase radiation sensitivity in tumors with PTEN mutations it will be necessary to develop drugs that correct for the faulty checkpoint processes, Pandita says. Work continues in the laboratory to further unravel the details of the checkpoint system and its role in radiation therapy resistance.

###

Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng S, Pagan J. Jeffrey J, Puc J, Kumar R, Feng Z, Powell SN, Bhat A, Yaguchi T, Wadhwa R, Kaul SC, Parsons R, Khanna KK, Pandita TK. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA repair. Cell Cycle. 2009 July 15;14(8):1-13.

Funding from National Institutes of Health supported this research.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked third in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Siteman Cancer Center is the only federally designated Comprehensive Cancer Center within a 240-mile radius of St. Louis. Siteman Cancer Center is composed of the combined cancer research and treatment programs of Barnes-Jewish Hospital and Washington University School of Medicine. Siteman has satellite locations in West County and St. Peters, in addition to its full-service facility at Washington University Medical Center on South Kingshighway.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.